Nabla Bio's latest AI model update generates de novo antibodies for GPCRs with therapeutic-grade properties within a few ...

Whether you’re working in a startup, academic lab, or biopharma R&D team, this eBook offers a window into what’s working now and what’s possible next.

The project could eventually add more than 400 manufacturing jobs and over 1,500 construction jobs during site development.

The French biotechnology firm aims to develop therapies for various neurological conditions using its non-replicating HSV-1 vector technology.

Study in mice found transient microglial depletion, or chemokine receptor blockade, resolved immunotherapy-related cognitive impairment.

HHS Secretary Robert F. Kennedy Jr. and biopharmas will negotiate drug prices individually. Kennedy could "propose a rulemaking plan to impose MFN pricing" if no “significant” progress has been made.

Gene therapies offer incredible promise for treating diseases with a genetic component. Several gene therapies are already ...

Astraveus' technology possesses the ability to simultaneously decrease manufacturing costs while increasing process ...

Researchers use generative AI to design synthetic enhancers that can effectively control gene expression in healthy mammalian ...

Ansa is accepting orders for synthetic DNA constructs ranging from 7.5 kb up to 50 kb for various applications.

Although gene-editing and other techniques can improve the production of microbe-based biologics, AI could push these drugs ...

To enhance CAR T therapies, scientists are actively studying TCR signaling and T-cell exhaustion mechanisms to improve CAR T ...